** Shares of gene therapy company MeiraGTx Holdings plc MGTX.O up 13.6% at $7.76 premarket
** Co says early-stage study data for its experimental gene therapy, rAAV8.hRKp.AIPL1, showed safety, efficacy and meaningful responses for treatment of genetic eye condition called retinal dystrophy
** Says children who were blind at birth were treated with the gene therapy and showed visual acuity in eyes after four or more weeks in small study
** The therapy showed improved functional vision and evidence of protection against progressive retinal degeneration, without serious adverse effects
** Retinal dystrophy is caused due to genetic deficiency of type of protein called AIPL1, which leads severe impairment of sight from birth
** Co says study data is published in medical journal The Lancet
** MGTX stock has risen ~16% in last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.